Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ICT 01

Next Previous
Drug Profile

ICT 01

Alternative Names: ICT-01; ICT01 - ImCheck Therapeutics

Latest Information Update: 23 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImCheck Therapeutics
  • Class Anti-infectives; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Butyrophilin inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma; Ovarian cancer; Squamous cell cancer; Urogenital cancer
  • Phase I/II Acute myeloid leukaemia; Haematological malignancies; Solid tumours
  • Research Infections

Most Recent Events

  • 21 Jul 2025 ICT 01 receives Orphan Drug status for Acute myeloid leukaemia in Europe
  • 18 Jul 2025 ICT 01 receives Orphan Drug status for Acute myeloid leukaemia in USA
  • 22 May 2025 Efficacy and adverse events data from the phase I/II EVICTION trial in Haematological malignancies released by ImCheck Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top